<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We evaluated the effect of N(G)-<z:chebi fb="13" ids="29785">nitro</z:chebi>-<z:chebi fb="0" ids="16467,29952">L-arginine</z:chebi>-<z:chebi fb="36" ids="29309">methyl</z:chebi>-<z:chebi fb="21" ids="35701">ester</z:chebi> (l-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e>, a nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthase [NOS] inhibitor) and <z:chebi fb="0" ids="16467,29952">L-arginine</z:chebi> (nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> substrate) on cerebral <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> dysfunction (hereafter referred to as "injury") after temporary middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAo) during <z:chebi fb="2" ids="5615">halothane</z:chebi> or etomidate anesthesia in spontaneously hypertensive rats </plain></SENT>
<SENT sid="1" pm="."><plain>Sixty minutes before MCAo, rats were randomized to 1 of 5 regimens (n = 8 per group): h/control, 1.2 minimum alveolar <z:chebi fb="164" ids="38867">anesthetic</z:chebi> concentration of <z:chebi fb="2" ids="5615">halothane</z:chebi>; h/L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e>, 1.2 minimum alveolar <z:chebi fb="164" ids="38867">anesthetic</z:chebi> concentration of <z:chebi fb="2" ids="5615">halothane</z:chebi> and L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e> (30 mg/kg); etomidate, an electroencephalographic (EEG) burst suppression dose of etomidate; e/L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e>, an EEG burst suppression dose of etomidate and L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e> (30 mg/kg); or e/L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e>/arg, an EEG burst suppression dose of etomidate, L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e> (30 mg/kg), and <z:chebi fb="0" ids="16467,29952">L-arginine</z:chebi> (bolus of 300 mg/kg with an infusion at 35 mg x kg(-1) x min(-1)) </plain></SENT>
<SENT sid="2" pm="."><plain>After 180 min of MCAo and 120 min of reperfusion, volume of injury was determined using 2,3,5-triphenytetrazolium stain </plain></SENT>
<SENT sid="3" pm="."><plain>Injury volume (mm(3), mean +/- sd) was larger in the etomidate group (153 +/- 17) than the <z:chebi fb="2" ids="5615">halothane</z:chebi> anesthetized h/control group (93 +/- 16) (P &lt; 0.05) but did not differ between the e/L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e> (162 +/- 17) and h/L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e> groups (155 +/- 26) </plain></SENT>
<SENT sid="4" pm="."><plain>Injury volume in the e/L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e>/arg group (88 +/- 15) was not different from the h/control group (93 +/- 16) and was less than that in either the etomidate or the e/L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e> groups (P &lt; 0.05) </plain></SENT>
<SENT sid="5" pm="."><plain>The data reproduce our previous observation that, relative to a <z:chebi fb="2" ids="5615">halothane</z:chebi>-anesthetized control state, etomidate has an adverse effect on ischemic injury in the setting of temporary focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Prior inhibition of NOS with L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e> resulted in no difference in the volume of injury between groups receiving etomidate or <z:chebi fb="2" ids="5615">halothane</z:chebi> (162 +/- 17 versus 155 +/- 26) </plain></SENT>
<SENT sid="7" pm="."><plain>Administration of a large dose of <z:chebi fb="0" ids="16467,29952">L-arginine</z:chebi> prevented the adverse effect of etomidate </plain></SENT>
<SENT sid="8" pm="."><plain>The data were obtained after only 2 h of reperfusion and therefore cannot be construed as representative of final neurologic outcome </plain></SENT>
<SENT sid="9" pm="."><plain>They nonetheless suggest that etomidate produces an adverse effect on <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> function early in the course of focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, in part, by inhibition of NOS </plain></SENT>
</text></document>